Source comparison
Comparison: MK-677 vs Other Growth Hormone Secretagogues
MK-677 (Ibutamoren) Ghrelin receptor agonist (GHSR-1a) 55–98% depending on baseline GH status Oral, once daily Sustained over 12–24 months without tachyphylaxis Gold standard for oral GH secretagogue research. Most robust human trial data GHRP-2 GH secretagogu
This comparison does not assign a generated winner or score.
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist (GHSR-1a)
- 55–98% depending on baseline GH status
- Oral, once daily
- Sustained over 12–24 months without tachyphylaxis
- Gold standard for oral GH secretagogue research. Most robust human trial data
- GHRP-2
- GH secretagogue receptor agonist
- 40–60% (single-dose studies only)
- Subcutaneous injection
- 2–4 hours post-injection
- Requires daily injections; no long-term trial data on sustained IGF-1 elevation
- GHRP-6
- 35–50% (single-dose studies only)
- Similar to GHRP-2 but with stronger appetite stimulation; limited chronic dosing data
- CJC-1295 (no DAC)
- GHRH analogue
- 20–35% (combined with GHRP in most studies)
- 30 minutes post-injection (short-acting)
- Typically used in combination protocols; not studied as monotherapy for IGF-1 elevation
- Exogenous rhGH
- Direct GH replacement
- Variable (dose-dependent, not mediated by endogenous secretion)
- Flat elevation for 12–24 hours
- Bypasses natural pulsatile release; suppresses endogenous GH; higher cost and regulatory restrictions